APA (7th ed.) Citation

Yang, Y., Zhou, H., Tang, L., Qiu, S., Han, Y., Ji, D., . . . Li, B. (2025). Izalontamab brengitecan, an EGFR and HER3 bispecific antibody–drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: A multicentre, randomised, open-label, phase 3 study in China. Lancet, 406(10516), 2235. https://doi.org/10.1016/S0140-6736(25)01954-3

Chicago Style (17th ed.) Citation

Yang, Yunpeng, et al. "Izalontamab Brengitecan, an EGFR and HER3 Bispecific Antibody–drug Conjugate, Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicentre, Randomised, Open-label, Phase 3 Study in China." Lancet 406, no. 10516 (2025): 2235. https://doi.org/10.1016/S0140-6736(25)01954-3.

MLA (9th ed.) Citation

Yang, Yunpeng, et al. "Izalontamab Brengitecan, an EGFR and HER3 Bispecific Antibody–drug Conjugate, Versus Chemotherapy in Heavily Pretreated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Multicentre, Randomised, Open-label, Phase 3 Study in China." Lancet, vol. 406, no. 10516, 2025, p. 2235, https://doi.org/10.1016/S0140-6736(25)01954-3.